Early COVID-19 and Protection from Omicron in a Highly Vaccinated Population in Ontario, Canada: a Matched Prospective Cohort Study

Overview

Journal BMC Infect Dis

Publisher Biomed Central

Date 2025 Feb 8

PMID 39923009

Authors

Altynay Shigayeva

Christopher Kandel

Lubna Farooqi

Zoe Zhong

Anne-Claude Gingras

Brenda L Coleman

Lois Gilbert

Wayne L Gold

Maria Major

Tony Mazzulli

Samira Mubareka

Jelena Vojicic

Jingyan Yang

Pingping Zhang

Catherine Martin

Moe H Kyaw

John M McLaughlin

Allison McGeer

Affiliations

Soon will be listed here.

Abstract

Objectives: Predictions regarding the on-going burden of SARS-CoV-2, and vaccine recommendations, require an understanding of infection-associated immune protection. We assessed whether early COVID-19 provided protection against Omicron infection.

Methods: We enrolled a cohort of adults in Ontario, Canada, with COVID-19 prior to October 2020 (early infection, EI), and a matched cohort with COVID-19 testing and a negative PCR (non-EI). Participants completed baseline surveys then surveys every two weeks until January 2023. Multivariable Cox regression was used to assess factors associated with COVID-19 infection during the first 14 months of Omicron.

Results: Overall, 624 EI (70%) and 175 (77%) non-EI participants met criteria for analysis; 590 (95%) EI and 164 (94%) non-EI had received at least 2 COVID-19 vaccine doses prior to Omicron. Of 624 EI, 175 (28%) had one SARS-CoV-2 re-infection and 8 (1.3%) had two, compared to 84 (48%) non-EI participants with one, 5 (2.9%) with two and 1 (0.6%) with 3 infections (P < 0.0001). In multivariable analysis of risk factors for Omicron infection, the overall hazard ratio (HR, 95%CI) associated with EI was 0.56 (0.43-0.74); HRs for BA.1/2, BA.4/5 and mixed BA.5/BQ.1/XBB periods were 0.66 (0.45-0.97), 0.44 (0.28-0.68) and 0.71 (0.32-1.56). EI and BA.1/2 infection combined reduced later Omicron infection (HR 0.07 (0.03-0.21) compared to no prior infection. Older age, non-White ethnicity, no children in household, and lower neighbourhood income were associated with reduced risk of infection.

Conclusions: In our highly vaccinated population, early SARS-CoV-2 infection was associated with a 44% reduction in symptomatic COVID-19 during the first 14 months of Omicron, providing significant protection against re-infection for more than 2 years.

References

Yung C, Pang D, Kam K, Lye D, Ong B, Chong C . BNT162b2 vaccine protection against omicron and effect of previous infection variant and vaccination sequence among children and adolescents in Singapore: a population-based cohort study. Lancet Child Adolesc Health. 2023; 7(7):463-470. PMC: 10185330. DOI: 10.1016/S2352-4642(23)00101-3. View

Chin E, Leidner D, Lamson L, Lucas K, Studdert D, Goldhaber-Fiebert J . Protection against Omicron from Vaccination and Previous Infection in a Prison System. N Engl J Med. 2022; 387(19):1770-1782. PMC: 9634863. DOI: 10.1056/NEJMoa2207082. View

Cauchi J, Dziugyte A, Borg M, Melillo T, Zahra G, Barbara C . Hybrid immunity and protection against infection during the Omicron wave in Malta. Emerg Microbes Infect. 2022; 12(1):e2156814. PMC: 9817114. DOI: 10.1080/22221751.2022.2156814. View

Lavell A, Tijdink J, Buis D, Smulders Y, Bomers M, Sikkens J . Why not to pick your nose: Association between nose picking and SARS-CoV-2 incidence, a cohort study in hospital health care workers. PLoS One. 2023; 18(8):e0288352. PMC: 10395815. DOI: 10.1371/journal.pone.0288352. View

Babouee Flury B, Gusewell S, Egger T, Leal O, Brucher A, Lemmenmeier E . Risk and symptoms of COVID-19 in health professionals according to baseline immune status and booster vaccination during the Delta and Omicron waves in Switzerland-A multicentre cohort study. PLoS Med. 2022; 19(11):e1004125. PMC: 9678290. DOI: 10.1371/journal.pmed.1004125. View

Altarawneh H, Chemaitelly H, Ayoub H, Hasan M, Coyle P, Yassine H . Protective Effect of Previous SARS-CoV-2 Infection against Omicron BA.4 and BA.5 Subvariants. N Engl J Med. 2022; 387(17):1620-1622. PMC: 9559315. DOI: 10.1056/NEJMc2209306. View

Tan C, Chiew C, Pang D, Lee V, Ong B, Wang L . Effectiveness of bivalent mRNA vaccines against medically attended symptomatic SARS-CoV-2 infection and COVID-19-related hospital admission among SARS-CoV-2-naive and previously infected individuals: a retrospective cohort study. Lancet Infect Dis. 2023; 23(12):1343-1348. DOI: 10.1016/S1473-3099(23)00373-0. View

Powell A, Kirsebom F, Stowe J, Ramsay M, Lopez-Bernal J, Andrews N . Protection against symptomatic infection with delta (B.1.617.2) and omicron (B.1.1.529) BA.1 and BA.2 SARS-CoV-2 variants after previous infection and vaccination in adolescents in England, August, 2021-March, 2022: a national, observational,.... Lancet Infect Dis. 2022; 23(4):435-444. PMC: 10032664. DOI: 10.1016/S1473-3099(22)00729-0. View

. Past SARS-CoV-2 infection protection against re-infection: a systematic review and meta-analysis. Lancet. 2023; 401(10379):833-842. PMC: 9998097. DOI: 10.1016/S0140-6736(22)02465-5. View

Brakefield W, Olusanya O, White B, Shaban-Nejad A . Social Determinants and Indicators of COVID-19 Among Marginalized Communities: A Scientific Review and Call to Action for Pandemic Response and Recovery. Disaster Med Public Health Prep. 2022; 17:e193. PMC: 9237492. DOI: 10.1017/dmp.2022.104. View

10.

Portmann L, de Kraker M, Frohlich G, Thiabaud A, Roelens M, Schreiber P . Hospital Outcomes of Community-Acquired SARS-CoV-2 Omicron Variant Infection Compared With Influenza Infection in Switzerland. JAMA Netw Open. 2023; 6(2):e2255599. PMC: 9932839. DOI: 10.1001/jamanetworkopen.2022.55599. View

11.

Virk A, Johnson M, Roellinger D, Scott C, Sampathkumar P, Breeher L . Hybrid Immunity Provides Protective Advantage Over Vaccination or Prior Remote Coronavirus Disease 2019 Alone. Open Forum Infect Dis. 2023; 10(5):ofad161. PMC: 10167982. DOI: 10.1093/ofid/ofad161. View

12.

Sundaram M, Calzavara A, Mishra S, Kustra R, Chan A, Hamilton M . Individual and social determinants of SARS-CoV-2 testing and positivity in Ontario, Canada: a population-wide study. CMAJ. 2021; 193(20):E723-E734. PMC: 8177943. DOI: 10.1503/cmaj.202608. View

13.

Wang L, Calzavara A, Baral S, Smylie J, Chan A, Sander B . Differential Patterns by Area-Level Social Determinants of Health in Coronavirus Disease 2019 (COVID-19)-Related Mortality and Non-COVID-19 Mortality: A Population-Based Study of 11.8 Million People in Ontario, Canada. Clin Infect Dis. 2022; 76(6):1110-1120. PMC: 9620355. DOI: 10.1093/cid/ciac850. View

14.

Ma H, Chan A, Baral S, Fahim C, Straus S, Sander B . Which Curve Are We Flattening? The Disproportionate Impact of COVID-19 Among Economically Marginalized Communities in Ontario, Canada, Was Unchanged From Wild-Type to Omicron. Open Forum Infect Dis. 2023; 10(1):ofac690. PMC: 9879750. DOI: 10.1093/ofid/ofac690. View

15.

Link-Gelles R, Weber Z, Reese S, Payne A, Gaglani M, Adams K . Estimates of Bivalent mRNA Vaccine Durability in Preventing COVID-19-Associated Hospitalization and Critical Illness Among Adults with and Without Immunocompromising Conditions - VISION Network, September 2022-April 2023. MMWR Morb Mortal Wkly Rep. 2023; 72(21):579-588. PMC: 10231940. DOI: 10.15585/mmwr.mm7221a3. View

16.

Carazo S, Skowronski D, Brisson M, Sauvageau C, Brousseau N, Gilca R . Estimated Protection of Prior SARS-CoV-2 Infection Against Reinfection With the Omicron Variant Among Messenger RNA-Vaccinated and Nonvaccinated Individuals in Quebec, Canada. JAMA Netw Open. 2022; 5(10):e2236670. PMC: 9568797. DOI: 10.1001/jamanetworkopen.2022.36670. View

17.

Bobrovitz N, Ware H, Ma X, Li Z, Hosseini R, Cao C . Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the omicron variant and severe disease: a systematic review and meta-regression. Lancet Infect Dis. 2023; 23(5):556-567. PMC: 10014083. DOI: 10.1016/S1473-3099(22)00801-5. View

18.

Altarawneh H, Chemaitelly H, Hasan M, Ayoub H, Qassim S, Almukdad S . Protection against the Omicron Variant from Previous SARS-CoV-2 Infection. N Engl J Med. 2022; 386(13):1288-1290. PMC: 8849180. DOI: 10.1056/NEJMc2200133. View

19.

Tartof S, Xie F, Yadav R, Wernli K, Martin E, Belongia E . Prior SARS-CoV-2 infection and COVID-19 vaccine effectiveness against outpatient illness during widespread circulation of SARS-CoV-2 Omicron variant, US Flu VE network. Influenza Other Respir Viruses. 2023; 17(5):e13143. PMC: 10209645. DOI: 10.1111/irv.13143. View